Allergan To Pay $300M For Glaucoma Treatment Developer
Allergan PLC will shell out $300 million for its latest acquisition, building out its eye treatment platform with the addition of venture capital-backed AqueSys Inc. and its implantable device for alleviating...To view the full article, register now.
Already a subscriber? Click here to view full article